MORLAIX & ALÈS, France--(BUSINESS WIRE)--HEMARINA, a French based marine biotechnology company dedicated to the R&D of universal oxygen carrier solutions, signed an industrial subcontracting agreement with LFB Biomanufacturing, LFB group's subsidiary specialized in the manufacturing of active protein solutions for pharmaceutical applications, leading up to the preparation of HEMO2life® regulatory batches. The HEMO2life® is a major breakthrough innovation in the field of organ preservation solutions. This product developed by HEMARINA enables preservation of organs and tissues under optimal physiological conditions due to oxygen contribution essential to their survival. Indeed, once the organ is removed from the donor it will go through an ischaemia/reperfusion cycle that could induce lesions and graft failures after transplant. HEMO2life® can make up for these two major issues during transplant as an oxygen carrier is facing free radicals during reperfusion.
Help employers find you! Check out all the jobs and post your resume.
